intensitytherapeutics.com (INTS): Long-Term Debt to Capital Ratio

Intensity Therapeutics Inc - graphic logo of issuer INTS

Geopolitical risks and disruptions in component logistics from Asia have triggered volatility captured by the long-term debt-to-equity ratio on the precise GURU.Markets chart, where the indicator reached 0.01. This has led Intensity Therapeutics (INTS) to depend on the successful commercialization of the INT230-6 method and the acceleration of its R&D pipeline to expedite the release of breakthrough clinical trial data.

INTS - Intensity Therapeutics Inc Long-Term Debt to Equity over the range 02/21/2024 - 10/28/2026

Intensity Therapeutics Inc (INTS) - metric breakdowns and financial figures

- price and consensus price forecast:
Market Price Intensity Tx|INTS - Price Target Chart
- market capitalization data:
Market Capitalization Intensity Therapeutics, Inc.|INTS - Enterprise Value
- book capitalization data:
Accounting Value per Share Intensity Therapeutics|INTS - Company Book Value|Market-to-Book Ratio intensitytherapeutics.com|INTS - Aggregate Company Assets
- debt and liquidity data:
Debt to Equity Intensity Therapeutics|INTS - Long-Term Debt to Equity|Current Liabilities to Capital Intensity Tx|INTS - Company Aggregate Debts|Debt to Net Assets Intensity Therapeutics, Inc.|INTS - Company Long-Term Liabilities|Short-Term Debt Intensity Therapeutics
Fundamental company valuation:INTS intensitytherapeutics.com
Brand item of Intensity Therapeutics, Inc.

Institutional capital assesses the financial stability of Intensity Therapeutics (INTS) through the lens of its debt load. This indicator compares liabilities with a maturity of over one year against total equity. By analyzing the share of long-term loans within the capital structure, investors can discern the company's actual dependence on external borrowings. For a biopharmaceutical firm utilizing DARA technology, this is critical, as excessive debt limits investments in the development of intratumoral therapy. Low values confirm the asset's reliability and the issuer's financial autonomy.

Who Intensity Therapeutics competes with

Long-Term Liabilities to Capital IBRX|Long-Term Debt to Equity Immunocore PLC IMCR|Long-Term Debt to Capital Ratio Janux Corp (JANX)|Arcus Biosciences, Inc. - Long-Term Debt to Capital|zymeworks.com - Long-Term Debt to Equity Ratio|TNGX (Tango Therapeutics, Inc.) - Long-Term Debt to Equity|IOVA: Long-Term Liabilities to Capital|Immatics Corp (IMTX) - Long-Term Debt to Equity|XNCR (Xencor Inc.) - Long-Term Debt to Equity|Long-Term Debt to Equity CMPX (Compass Therapeutics)|Long-Term Liabilities to Capital replimune.com|LYEL: Long-Term Debt to Capital|Long-Term Indebtedness to Equity Innate Pharma SA IPHA|PYXS: Long-Term Debt to Equity Ratio|CGEN - Long-Term Liabilities to Capital|Long-Term Debt to Equity Ratio IO Biotech, Inc. (IOBT)|STRO - Long-Term Debt to Capital Coefficient|MiNK Therapeutics - Long-Term Debt to Capital|HOWL (Werewolf Therapeutics, Inc.) - Ratio of Long-Term Indebtedness to Capital|Long-Term Debt to Equity IMMX|Long-Term Debt to Equity Ratio ALXO|Long-Term Debt to Equity CUE (Cue Biopharma)|Long-Term Debt to Equity Ratio pdsbiotech.com PDSB|Long-Term Debt to Equity Ratio SONN (Sonnet BioTherapeutics Holdings)|MAIA Biotech - Long-Term Debt to Capital|Liminatus Pharma Corp (LIMN) - Long-Term Debt to Equity|LVTX: Long-Term Debt to Capital Ratio|Long-Term Debt to Equity NXTC|Long-Term Liabilities to Capital Leap Therapeutics|Sensei Biotherapeutics Inc - Long-Term Debt to Equity Ratio|Long-Term Indebtedness to Equity Theriva Biologics Inc (TOVX)|Long-Term Debt to Equity Ratio Gritstone bio, Inc.|Long-Term Loans to Capital Ratio Kineta Corp (KA)|Long-Term Debt to Capital NexImmune, Inc.|Long-Term Debt to Capital Coefficient Turnstone Biologics Corp TSBX|VCNX (Vaccinex) - Long-Term Debt to Capital|HARP: Long-Term Liabilities to Capital